Search Results - "Lu, D.R"

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial by Rugo, H.S., Diéras, V., Gelmon, K.A., Finn, R.S., Slamon, D.J., Martin, M., Neven, P., Shparyk, Y., Mori, A., Lu, D.R., Bhattacharyya, H., Bartlett, C.H.u.a.n.g., Iyer, S., Johnston, S., Ettl, J., Harbeck, N.

“…Patient-reported outcomes are integral in benefit–risk assessments of new treatment regimens. The PALOMA-2 study provides the largest body of evidence for…”
Get full text

Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study by Faivre, S., Niccoli, P., Castellano, D., Valle, J.W., Hammel, P., Raoul, J.-L., Vinik, A., Van Cutsem, E., Bang, Y.-J., Lee, S.-H., Borbath, I., Lombard-Bohas, C., Metrakos, P., Smith, D., Chen, J.-S., Ruszniewski, P., Seitz, J.-F., Patyna, S., Lu, D.R., Ishak, K.J., Raymond, E.

“…In a phase III trial in patients with advanced, well-differentiated, progressive pancreatic neuroendocrine tumors, sunitinib 37.5 mg/day improved…”
Get full text

XBP1 promoter polymorphism modulates platinum-based chemotherapy gastrointestinal toxicity for advanced non-small cell lung cancer patients by Peng, J, Chen, Y.Y, Yang, L.X, Zhao, X.Y, Gao, Z.Q, Yang, J, Wu, W.T, Wang, H.J, Wang, J.C, Qian, J, Chen, H.Y, Jin, L, Bai, C.X, Han, B.H, Lu, D.R

“…Abstract Background The X-box binding protein 1 (XBP1) is a critical transcription factor in the endoplasmic reticulum stress response, which is essential for…”
Get full text

73TiP Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3 by Iwata, H., Hamilton, E.P., Ma, C.X., De Laurentiis, M., Hurvitz, S.A., Wander, S.A., Danso, M.A., Lu, D.R., Perkins, J., Liu, Y., Tran, L., Anderson, S., Chappey, C., Yang, D.Z., Campone, M.

Get full text

6501 Sunitinib (SU) vs placebo for treatment of progressive, well- differentiated pancreatic islet cell tumours: results of a phase III, randomised, double-blind trial by Raoul, J.L, Niccoli, P, Bang, Y.J, Borbath, I, Lombard-Bohas, C, Metrakos, P, Vinik, A, Lu, D.R, Blanckmeister, C, Raymond, E

Get full text

Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases by Turner, N.C., Finn, R.S., Martin, M., Im, S.-A., DeMichele, A., Ettl, J., Diéras, V., Moulder, S., Lipatov, O., Colleoni, M., Cristofanilli, M., Lu, D.R., Mori, A., Giorgetti, C., Iyer, S., Bartlett, C. Huang, Gelmon, K.A.

“…This report assesses the efficacy and safety of palbociclib plus endocrine therapy (ET) in women with hormone receptor-positive, human epidermal growth factor…”
Get full text

264TiP TACTIVE-K: Phase Ib/II study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer by Telli, M.L., Gawryletz, C., Wei, M., Patnaik, A., Lu, D.R., Mazzoletti, M., Valota, O., Parmar, S., Tan, W., Mukohara, T.

Get full text

Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER + /HER2– advanced breast cancer (ABC) by Finn, R., Jiang, Y., Rugo, H., Moulder, S.L., Im, S.-A., Gelmon, K.A., Dieras, V., Martin, M., Joy, A.A., Toi, M., Gauthier, E., Lu, D.R., Bartlett, C.H., Slamon, D.

Get full text

257TiP VERITAC-2: A global, randomized phase III study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer by Hamilton, E., Ma, C.X., De Laurentiis, M., Iwata, H., Hurvitz, S.A., Wander, S.A., Danso, M.A., Lu, D.R., Perkins, J., Liu, Y., Tran, L., Anderson, S., Campone, M.

Get full text

Impact of palbociclib plus letrozole on health related quality of life (HRQOL) compared with letrozole alone in treatment naïve postmenopausal patients with ER+ HER2- metastatic breast cancer (MBC): results from PALOMA-2 by Rugo, H., Dieras, V., Gelmon, K.A., Finn, R., Slamon, D., Miguel, M., Neven, P., Ettl, J., Shparyk, Y., Mori, A., Lu, D.R., Bhattacharyya, H., Bartlett, C.H., Iyer, S., Johnston, S., Harbeck, N.

Get full text

116O Palbociclib (PAL) plus letrozole (L) as first-line (1L) therapy (tx) in postmenopausal Asian women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) by Im, S.-A., Mukai, H., Park, I.H., Masuda, N., Shimizu, C., Kim, S.B., Im, Y.-H., Ohtani, S., Bartlett, C.H., Lu, D.R., Mori, A., Gauthier, E., Finn, R.S., Toi, M.

Get full text

Clinical outcomes in patients (pts) with estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC) with objective response (OR) or without objective response (non-OR) in PALOMA-2 by Rugo, H.S., Finn, R.S., Gelmon, K.A., Joy, A.A., Lipatov, O.N., Harbeck, N., Castrellon, A., Mukai, H., Walshe, J.M., Mori, A., Gauthier, E., Lu, D.R., Bananis, E., Martín, M., Dieras, V.

Get full text

Arsenic-related skin lesions and glutathione S-transferase P1 A1578G (Ile105Val) polymorphism in two ethnic clans exposed to indoor combustion of high arsenic coal in one village by Lin, Guo-Fang, Du, Hui, Chen, Ji-Gang, Lu, Hong-Chao, Guo, Wei-Chao, Meng, Hong, Zhang, Tian-Bao, Zhang, Xin-Jiang, Lu, Da-Ru, Golka, Klaus, Shen, Jian-Hua

“…OBJECTIVESA total of 2402 patients with arsenic-related skin lesions, such as hyperkeratosis, hyperpigmentation or hypopigmentation, or even skin cancer in a…”
Get full text

Nonlinear data fitting for controlled release devices: An integrated computer program by Lu, D.R., Abu-Izza, K., Mao, F.

“…A computer program, MSFIT, was developed for nonlinear fitting of release data from controlled release devices. The program is written in the C language, based…”
Get full text

Micromachined glucose sensor and K + ISE based on containment array by Zhu, J.Z, Xie, J.F, Lu, D.R, Zhang, G.X, Zhang, Z.R

“…This paper reports fabrication and characterization of an integrated glucose microsensor and potassium ion selective microelectrode based on pyramidal…”
Get full text